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Aims The aim of this study was to describe the characteristics of patients with atrial ﬁbrillation (AF) enrolled in the Central
Registry of the German Competence NETwork on Atrial Fibrillation (AFNET) and to assess current medical practice
in patients treated at various levels of medical care in Germany.
Methods
and results
From February 2004 to March 2006, 9582 ambulatory and hospitalized patients with ECG-documented AF were
enrolled by 194 participating study centres from all levels of medical care in Germany. Clinical type of AF was
reported as paroxysmal in 2893, persistent in 1873, and permanent in 3134 patients or classiﬁed as a ﬁrst
episode in 1035 patients. Predisposing conditions were common and present in 87.6% of the patients. Most patients
were symptomatic with AF (75.1%). Rhythm control in persistent AF was provided to 53.4% of the symptomatic
patients and to 47.8% of the patients without symptoms. Anticoagulation for stroke prevention was given to
71.4% of the patients considered eligible by applicable guidelines and to 48.4% of patients with low risk where guide-
lines do not recommend anticoagulation.
Conclusion This registry provides insight into current medical care of patients with AF in Germany. The use of oral anticoagula-
tion in eligible patients was among the highest reported, whereas decisions on rate and rhythm control often do not
follow current recommendations.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
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Introduction
Atrial ﬁbrillation (AF) is the most frequent sustained arrhythmia in
clinical practice and associated with a high risk of stroke, heart
failure, and hospitalization.
1–3 Ageing of the population and the
accumulation of predisposing conditions will cause the prevalence
of AF to rise by at least 2.5-fold by the year 2050.
4 For optimized
diagnostic and therapeutic management, patient characteristics and
determinants of clinical course and complications will be essential.
Clinical studies over the last 20 years have provided a frame-
work for guidelines on care in AF.
5–8 However, it is difﬁcult to
establish the level of adherence to guidelines in every day clinical
*Corresponding author. Tel: þ49 89 7095 2360, Fax: þ49 89 7095 8870, Email: michael.nabauer@med.uni-muenchen.de (M.N.) or gerhard.steinbeck@med.uni-muenchen.de
(G.S.)
Published on behalf of the European Society of Cardiology. All rights reserved. & The Author 2009. For permissions please email: journals.permissions@oxfordjournals.org
The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access version of this article
for non-commercial purposes provided that the original authorship is properly and fully attributed; the Journal, Learned Society and Oxford University Press are attributed as the
original place of publication with correct citation details given; if an article is subsequently reproduced or disseminated not in its entirety but only in part or as a derivative work this
must be clearly indicated. For commercial re-use, please contact journals.permissions&oxfordjournals.org.
Europace (2009) 11, 423–434
doi:10.1093/europace/eun369practice, given, among other things, the often limited feasibility of
diagnostics and treatment in a preferentially elderly population
or constraints such as patient preference and compliance. A
limited number of previous national and international surveys
and registries have provided information on the management of
patients with AF,
9–13 usually focusing on speciﬁc patient subsets
such as those cared for by cardiologists
9,10,14 or general prac-
titioners.
15,16 There has been increasing awareness of recent guide-
lines and clinical trials on AF, importantly of the ACC/AHA/ESC
guidelines published in 2001,
5 updated in 2006,
6 which may have
inﬂuenced diagnostic and therapeutic decision-making, even
though the impact of such guidelines on clinical practice has
been disputed.
The German Competence NETwork on Atrial Fibrillation
(AFNET), established in 2003 and funded by the Federal Ministry
for Education and Research (BMBF), has initiated a large nation-
wide patient registry to evaluate current daily care of patients
with AF in Germany. The study included patients with AF recruited
by general practitioners, internists, and cardiologists, all ofﬁce-
based, as well as by community hospitals and tertiary care or
specialized referral centres. This is the ﬁrst report on character-
istics and initial management of the patients in the central registry
of the German AFNET.
Methods
The central patient registry of the German AFNET is a multicentre
prospective observational study designed to enrol patients at all
levels of medical care. The project is organized as a network consisting
of 13 regional coordinating centres (10 university departments of car-
diology and 3 academic hospitals), each coordinating the activities in
the regional hospital departments (59) and in the practices of
ofﬁce-based cardiologists (63), internists (36), and general prac-
titioners (23). The central administrative ofﬁce of the network is
located at the University of Mu ¨nster, Germany (for details see:
www.kompetenznetz-vorhofﬂimmern.de).
Enrolment sites were selected to provide a representative picture of
current medical practice throughout Germany and include all levels of
medical care (see Appendix 3 for participating centres, afﬁliation, and
status). Patients were recruited from medical wards, outpatient clinics,
and by ofﬁce-based physicians (cardiologists, internists, and general
practitioners). Management of patients was according to local
medical practice. All participating centres agreed to consecutive enrol-
ment of all patients with AF to minimize patient selection bias.
Patients were included in the registry if they were 18 years or older
and had AF documented on ECG or Holter ECG recording, either at
the time of enrolment or during the preceding 12 months. Patients
with atrial ﬂutter as the sole arrhythmia were not included. Informed
consent was obtained in written from all patients included in the reg-
istry. Patient follow-up is planned for up to 5 years after enrolment.
Data collection
The web-based electronic data capture system MARVIN was managed
by the Institute for Clinical Cardiovascular Research (IKKF, Munich,
Germany; www.ikkf.de). The primary route of data entry was via the
internet. The data-cleaning process included automated range
checks, with change requests displayed immediately to the user. A
two-step query process included automated queries related to single
data ﬁelds (edit checks) and manually created queries. The programme
was managed to comply with data protection requirements and secur-
ity standards (FDA 21, CFR part 11). All information was kept conﬁ-
dential and data transmission was encrypted.
Data analysis
Data analysis was performed at the ‘Institut fu ¨r Herzinfarktforschung
Ludwigshafen an der Universita ¨t Heidelberg’ (Institute for Research
in Myocardial Infarction Ludwigshafen of the University of Heidelberg;
www.herzinfarktforschung.de), located in Ludwigshafen/Rhein,
Germany. The data are presented as absolute numbers and percen-
tages. Unless otherwise stated, mean values and standard deviations
are given. Dichotomous variables were compared by the x
2 test
(Pearson) and continuous variables by the Mann–Whitney U-test. A
two-sided alpha level of 0.05 was considered statistically signiﬁcant.
Multivariate analysis was used to adjust for differences in patient
characteristics at various levels of medical care on anticoagulation
strategy. The statistical computations were performed using SAS,
version 9.1 (Cary, NC, USA).
Results
Patient enrolment
Between 16 February 2004 and 31 March 2006, a total of 9582
patients were enrolled by 194 participating study centres (for a
list of centres, see Appendix 3). 3785 patients (39.5%) were
enrolled by the 13 regional coordinating centres. Community
hospitals (59 sites) enrolled 2348 (24.5%) patients, ofﬁce-based
cardiologists 2638 (27.5%, 63 sites), and internists and general
practitioners 811 (8.5%, 59 sites). Therefore, the survey represents
patients treated at all levels of medical care from large university
medical centres to ofﬁce-based general practitioners.
Patient characteristics on admission
or at consultation
Characteristics of the 9582 patients included in the registry are
shown in Table 1. Age of the patients ranged from 18 to 98 years
(mean age 68.4 + 11.0; 29.2% 75 years or older), and women
were older than men (Figure 1), consistent with later onset of AF
in women as observed in epidemiological studies.
17 At the time of
enrolment into the registry, 1035 patients (10.8%) presented with
their ﬁrst episode of AF, 2893 (30.2%) with paroxysmal AF, 1873
(19.5%) with persistent AF, and 3141 (32.8%) with permanent AF
[unknown type of AF in 640 (6.7%) patients, Table 1].
5,18
Only 12.4% of the patients were diagnosed to have ‘lone AF’,
implying the absence of detectable concomitant disease known
to promote AF. By far the most prevalent concomitant condition
was arterial hypertension (69.2% of patients). Other cardiac dis-
eases commonly present were valvular heart disease (36.3%;
only 3.7% of which were rheumatic in origin), coronary artery
disease (28.1%), symptomatic heart failure [New York Heart
Association (NYHA) II to NYHA IV, 29.0%], and various forms
of cardiomyopathy (10.7%), all of which tended to be more preva-
lent in patients with permanent AF compared with paroxysmal or
persistent AF (Table 1). The high proportion of patients with valv-
ular heart disease was mostly due to a high prevalence of mitral
valve regurgitation, which was reported to be present in 29.1%
of the patients, preferentially in patients with persistent (30.3%)
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Table 1 Patient characteristics
First detected
10.8% (n 5 1035)
Paroxysmal
30.2% (n 5 2893)
Persistent
19.5% (n 5 1873)
Permanent
32.8% (n 5 3141)
P-value
Demographics
Age (years) 67.0 + 12.3 65.5 + 11.3 67.6 + 11.2 71.7 + 9.2 *
Female gender (%) 40.1 41.2 35.2 38.7 *
Concomitant disease
Hypertension (%) 68.9 65.9 70.6 71.1 *
Coronary artery disease (%) 26.8 25.0 28.4 31.0 *
Old infarction (%) 14.5 11.2 14.0 14.5
Previous PCI/CABG (%) 14.7 16.7 16.6 17.6
Angina (%) 15.5 12.9 13.2 13.1
Heart failure (%) 31.6 24.1 41.4 45.2 *
Valvular heart disease (%) 27.7 25.1 37.0 48.1 *
Rheumatic origin (%) 3.1 2.5 3.3 5.3 *
Non-rheumatic origin (%) 24.6 22.6 33.7 42.7 *
Valve replacement (%) 2.4 3.9 4.3 7.6 *
Cardiomyopathy (%) 7.2 6.8 13.6 13.8 *
Tachycardiomyopathy (%) 0.3 0.2 1.0 0.2 *
Hypertrophic (%) 1.7 1.0 1.4 0.7
Dilated (%) 4.2 3.5 7.2 9.5 *
Other type (%) 1.1 2.0 3.4 3.1 *
Sick sinus syndrome (%) 3.9 8.8 5.3 6.7 *
Chronic obstructive pulmonary disease (%) 10.4 10.2 10.6 13.5 *
Hypothyroidism (%) 5.0 5.7 5.1 5.5
Overt hyperthyroidism (%) 3.9 3.3 5.1 4.0
Subclinical hyperthyroidism (%) 3.5 2.8 2.6 2.5
Idiopathic AF (%) 13.9 17.0 10.0 9.3 *
Cardiovascular risk factors
Diabetes mellitus (%) 20.5 15.8 21.3 27.6 *
Hyperlipidaemia (%) 48.3 46.8 44.7 45.8
Current smoker (%) 11.6 8.7 7.4 5.2 *
Previous smoker (%) 32.4 33.9 38.4 37.9 *
No regular exercise (%) 44.6 41.5 46.7 53.3 *
Family history of CAD (%) 27.5 34.2 31.0 27.1 *
Comorbidities
Previous thrombo-embolism (%) 8.1 11.9 13.8 16.0 *
Stroke (%) 3.7 5.0 6.7 8.5 *
TIA (%) 2.1 3.3 4.0 4.1
Other thrombo-embolism (%) 2.7 4.3 4.3 5.3
Prior major bleeding (%) 0.9 1.5 2.2 2.8 *
Malignancy (%) 7.2 7.4 7.3 9.6 *
Peripheral vascular disease (%) 5.2 5.3 6.7 8.7 *
Renal failure (%) 9.2 9.6 11.2 14.5 *
Previous interventions
Pharmacological conversion (%) 11.1 16.2 8.9 2.6 *
Electrical cardioversion (%) 9.5 17.1 22.7 6.9 *
Catheter ablation (%) 1.1 7.5 3.3 1.9 *
Pacemaker implantation (%) 1.7 7.5 5.2 9.2 *
ICD implantation (%) 1.0 1.3 2.6 2.6 *
Surgery for AF (%) 0.1 0.2 0.1 0.3
PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting; CAD, coronary artery disease; TIA, transient ischaemic attack; ICD, implantable cardioverter
deﬁbrillator.
*Difference with P , 0.001 among the four AF types.
Characteristics of patients with AF 425and permanent (39.7%) AF. Diabetes mellitus (21.7%) and lack of
regular physical activity (47.4%) were frequently reported and
more common in patients with permanent AF (Table 1).
Non-cardiac diseases frequently present were chronic obstruc-
tive pulmonary disease, increasing in prevalence from paroxysmal
(10.2%) to permanent AF (13.5%), and renal failure, also more
common in permanent (14.5%) than paroxysmal (9.6%) AF. This
contrasts with thyroid disease, which was distributed equally in
all clinical types of AF (11.8–12.8%; Table 1). Previous thrombo-
embolic events were common and present with increasing fre-
quency from ﬁrst episodes (8.1%) to permanent AF (16.0%).
Approximately half of the events were strokes (Table 1).
Permanent AF was strongly associated with the presence of con-
comitant cardiac and non-cardiac disease and with risk factors for
stroke (Figure 2). In the absence of concomitant disease, only 18.7%
of the patients had permanent AF, increasing to 54.8% in patients
with ﬁve or more concomitant diseases. The increase in permanent
AF with the accumulation of co-morbidities was almost exclusive at
the cost of paroxysmal AF, with the fraction of patients in persistent
AF remaining essentially constant (15.2–22.7%).
There was no relationship between the presence of hyperlipi-
daemia, angina pectoris, or history of percutaneous coronary inter-
vention or bypass surgery and the clinical type of AF. Current
smoking was reported with decreasing frequency in persistent
(7.4%) and permanent forms (5.2%) of AF when compared with
those presenting with a ﬁrst episode (11.6%) or paroxysmal AF
(8.7%). Previous smoking was reported to be most prevalent in
persistent (38.4%) and permanent (37.9%) AF when compared
with those presenting with a ﬁrst episode (32.4%, Table 1;
P , 0.001).
Symptoms were assessed on the basis of the presence or
absence of palpitations, dyspnoea, chest pain, dizziness, or fatigue
(see Appendix 1) and NYHA functional class. Symptoms reported
most frequently were palpitations, especially in paroxysmal AF
(54.9%) or during a ﬁrst episode (54.3%), which were also the
most symptomatic types of AF. Dyspnoea was a frequently
reported symptom and most prevalent in persistent (47.5%) and
permanent AF (47.5%). Higher degrees of heart failure were
much more common in patients with permanent AF (37.3%
were classiﬁed at least NYHA class II and 13.3% at least NYHA
class III) than with paroxysmal AF (18.4% at least NYHA class II
and 6.8% at least NYHA class III). The lack of control of heart
rate was evident in patients presenting with their ﬁrst episode of
AF (mean heart rate during AF, 109 + 30 bpm; 45.0% of the
patients above 110 bpm) or with paroxysmal AF (mean heart
rate, 100 + 29 bpm; 33.1% of the patients above 110 bpm), poss-
ibly also responsible for the more symptomatic nature of these
conditions (Table 2).
Diagnostic procedures used
Transthoracic echocardiography was used preferentially in patients
presenting with a ﬁrst episode of AF (74.0%) and with permanent
AF (68.2%, Table 3; only echocardiography performed within 3
months before inclusion was an accepted entry). Chest X-rays
were used only in a few patients (18.9%). Thyroid function was
reported to be studied in the majority of the patients (57.5% of
all patients, usually within the preceding 6 months) and in 64.5%
of patients on amiodarone at the time of inclusion.
Drug therapy
Drug therapy was evaluated at the end of the enrolment visit
(discharge from hospital or end of outpatient visit). Information
on medication was available for 8962 of 9582 (93.5%) patients
(Table 4). Beta-blockers and digitalis were the rate control drugs
used most frequently in the overall population (65.7 and 35.5%,
respectively). In permanent AF, beta-blockers (59.2%) and digitalis
(50.9%) were used more frequently than calcium channel blockers
(verapamil 10.2% and diltiazem 1.0%). In the other types of AF, the
use of beta-blockers was even more common, ranging from 67.4%
in paroxysmal AF to 73.7% in patients with a ﬁrst detected episode
of AF. Digitalis was used less frequently in these types of AF
(paroxysmal AF 21.4% and persistent AF 35.2%; Table 4).
Figure 2 Shift of atrial ﬁbrillation type from paroxysmal to per-
manent in relation to concomitant conditions known to promote
atrial ﬁbrillation. Factors counted were age  75 years, hyperten-
sion, diabetes, cardiomyopathy, heart failure, valve disease or
replacement.
Figure 1 Age distribution for men and women enrolled in the
central patient registry of the German AFNET. The male/female
ratio was 1.6; 22.2% of men and 40.1% of women were 75
years or older.
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inhibitors or angiotensin-II receptor antagonists was very
common. In the total study cohort, 47.0% of the patients were
treated with ACE inhibitors and 16.2% of the patients were
treated with AT II antagonists (Table 4).
Rate and rhythm control
Rhythm control with electrical or pharmacological cardioversion
or ablation was performed in 53.4% of the patients with persistent
AF and current AF-related symptoms (details in Appendix 1) and in
47.8% of the patients in persistent AF not reporting AF-related
symptoms. However, the use of electrical or pharmacological car-
dioversion or ablation in patients with persistent AF increased with
the number of reported symptoms from 40.8% (no symptoms) to
49.5% (one symptom reported) and 60.6% (all ﬁve symptoms
present), suggesting a relevant impact of symptom burden on
treatment strategy.
Anti-arrhythmic drugs (classes I and III) were given to 21.3% of
the patients, primarily to patients with paroxysmal (ﬂecainide,
14.7%; propafenone, 2.9%; sotalol, 5.3%; amiodarone, 13.8%) and
persistent AF (ﬂecainide, 7.9%; propafenone, 1.2%; sotalol, 2.0%;
amiodarone, 13.1%). In contrast, anti-arrhythmic drugs were
given only occasionally to patients with permanent AF (ﬂecainide,
1.1%; propafenone, 0.5%; sotalol, 2.3%). Amiodarone was given to
4.4% of the patients with permanent AF.
Rhythm control drugs were usually combined with rate control
drugs, and 63.4% of the patients on class I agents also received
beta-blockers or calcium channel blockers (verapamil or diltiazem).
Flecainide was more frequently combined with rate control drugs
(66.5%) than propafenone (50.0%). Similarly, the class III drug
amiodarone was frequently combined with rate control drugs
(beta-blockers, 62.3%; verapamil or diltiazem, 2.5%).
After electrical cardioversion, 16.5% of the patients received
class I anti-arrhythmic drugs (ﬂecainide, 14.6% and propafenone,
1.9%), 3.5% sotalol, and 22.9% amiodarone to prevent recur-
rences of AF. Beta-blockers only were given to 47.8% of the
patients after cardioversion, calcium antagonists (verapamil or dil-
tiazem) to 2.5%. In only 8.3% of the patients, no anti-arrhythmic
drugs, beta-blockers, or calcium antagonists, were given after
electrical cardioversion. Only a rare patient (15/9582) with a
risk proﬁle for class I anti-arrhythmic drugs (deﬁned as previous
myocardial infarction or coronary bypass surgery or severe LV
dysfunction on echocardiography) received class I anti-arrhythmic
drugs.
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Table 2 Admission/consultation information
First detected
10.8% (n 5 1035)
Paroxysmal
30.2% (n 5 2893)
Persistent
19.5% (n 5 1873)
Permanent
32.8% (n 5 3141)
P-value
Reason for admission/consultation
AF (%) 71.7 71.4 66.0 46.5 *
Other cardiovascular disease (%) 22.0 23.3 26.4 43.4 *
Non-cardiovascular disease (%) 6.3 5.3 7.6 10.1 *
Symptoms
Current AF symptoms (%) 82.6 78.7 76.7 69.6 *
Palpitations (%) 54.3 54.9 41.4 26.1 *
Chest pain (%) 22.7 21.2 18.8 15.1 *
Dyspnoea (%) 44.3 38.7 47.5 47.5 *
Dizziness (%) 27.2 28.7 24.9 21.9 *
Fatigue (%) 49.5 47.6 49.0 38.4 *
No symptoms (%) 17.4 21.3 23.3 30.4 *
Heart failure NYHA class III/IV (%) 11.6 6.8 14.8 13.3 *
Physical examination
BMI (kg/m
2) 27.6 + 4.7 27.5 + 4.6 27.8 + 4.6 27.8 + 4.8
Systolic BP (mmHg) 132.5 + 19.8 130.4 + 18.7 130.3 + 19.8 133.7 + 20.3 *
Diastolic BP (mmHg) 78.8 + 11.9 78.2 + 10.9 78.8 + 11.6 80.2 + 12.2 *
ECG
Atrial ﬁbrillation (%) 75.4 58.4 88.1 94.7 *
Heart rate in AF (bpm) 108.6 + 30.2 100.2 + 28.7 88.0 + 25.0 79.9 + 19.9 *
Heart rate in AF .110 bpm (%) 45.0 33.1 15.8 7.4 *
Left BBB (%) 6.0 6.2 8.0 8.8 *
Right BBB (%) 5.5 6.5 9.1 8.2 *
QRS duration (ms) 94.5 + 23.5 98.5 + 27.7 102.0 + 28.0 104.6 + 30.5 *
BMI, body mass index; BP, blood pressure; BBB, bundle branch block; TTE, transthoracic echocardiography.
*Difference with P , 0.001 among the four AF types.
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Ablation procedures for AF have been used frequently even before
inclusion into the registry, with 7.5% of the patients in paroxysmal
AF and 3.3% of patients in the persistent AF treated previously
with an ablation procedure. After enrolment, patients in paroxys-
mal AF were treated with an ablation procedure in 11.9%, in per-
sistent AF in 5.7%, and in permanent AF in 1.7%. Patients with a
ﬁrst episode received an ablation procedure in only 1.5%. Consid-
ering all ablations performed, most of them were applied to
patients with paroxysmal AF (64.6%) and persistent AF (20.0%),
and only a few (10.3%) were in patients with permanent AF
(‘long-lasting persistent AF’
19) or after a ﬁrst episode (2.9%).
Ablation procedures were almost exclusively performed at the
regional coordinating centres (10 university departments of
cardiology and 3 academic hospitals).
Anti-thrombotic treatment
Stroke prevention remains one of the primary treatment goals in
patients with AF. On the basis of the stroke risk stratiﬁcation of
the ACC/AHA/ESC 2001 Guidelines, 90.8% of the patients in the
registry would be considered to be at high or very high risk for
stroke, mandating anticoagulation. This includes patients under-
going a cardioversion or ablation procedure. After excluding
patients with documented potential contraindications (prior
major bleeding or haemorrhagic stroke, 2.5% and malignancy,
8.1%), 67.5% of the 7194 patients requiring anticoagulation
did receive oral anticoagulants. A further 3.9% received low-
molecular-weight heparin (LMWH), with the intention to
provide adequate anticoagulation, resulting in a total of 71.4% of
the eligible patients on anticoagulation therapy (Figure 3 and
Table 5). Antiplatelet drugs were given in 16.9% of the patients
as the only anti-thrombotic treatment (Figure 3). Still, 11.2%
of the patients eligible for anticoagulation received no anti-
thrombotic treatment. Of the 710 patients not considered
candidates for anticoagulation, 351 (49.4%) received oral anticoa-
gulation (46.2%) or LMWH (3.2%) for anticoagulation purposes,
indicating that a signiﬁcant portion of low-risk patients may be
overtreated.
Discussion
The age distribution of the patients with AF highlights the upcom-
ing dimension of this disease in an ageing population (Figure 1).
1,4,20
With 40.1% of women and 22.2% of men 75 years or older, special
requirements and limitations in care for these patients will apply,
also pertaining treatment with oral anticoagulants. Rheumatic
valvular heart disease, which used to be an important underlying
disease for the development of AF,
9,20 was present in only 3.7%
of the patients, reﬂecting a change in the cardiac disease. The
contemporary patients with AF are likely to have multiple comor-
bidities, most importantly hypertension, diagnosed in almost 70%
of the patients in this registry, as opposed to 50% in the general
population in Germany.
21 Usually, hypertension was accompanied
by other cardiac and non-cardiac diseases. The absence of predis-
posing cardiac diseases resulting in classiﬁcation as ‘lone AF’
5,6,22
was only seen in a small percentage of patients (12.4% of all
patients), similar to earlier estimates
23 and results form the Euro
Heart Survey (10.2%).
10
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Table 3 Diagnostics and interventions
First detected
10.8%(n 5 1035)
Paroxysmal
30.2% (n 5 2893)
Persistent
19.5% (n 5 1873)
Permanent
32.8% (n 5 3141)
P-value
Diagnostics
a
TTE (%) 74.0 60.3 61.4 68.2 *
Chest X-ray (%) 30.2 17.9 22.3 15.7 *
Holter monitoring (%) 20.2 19.0 17.6 11.3 *
Exercise test (%) 10.7 10.1 12.0 12.4
TEE (%) 19.6 18.0 20.0 9.0 *
Electrophysiology (%) 1.9 6.7 3.4 1.2 *
Serum TSH measurement (%) 75.8 63.8 66.7 41.9 *
Interventions
b
Pharmacological conversion (%) 13.2 9.3 6.2 0.7 *
Electrical cardioversion (%) 24.4 14.0 24.1 2.9 *
Catheter ablation (%) 1.5 11.9 5.7 1.7 *
Pacemaker implantation (%) 2.1 4.8 3.7 2.4 *
ICD implantation (%) 1.4 1.0 0.9 1.1
AF surgery (%) 0.6 0.8 1.0 0.4
TTE, transthoracic echocardiography; TEE, transoesophageal echocardiography; ICD, implantable cardioverter deﬁbrillator.
aPrior to or during qualifying admission or consultation.
bDuring qualifying admission or consultation.
*Difference with P , 0.001 among the four AF types.
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Although classiﬁcation of AF into different types is clinically useful
to select for the appropriate treatment, the shortcomings of such
classiﬁcations becomes obvious when applied at a single point in
time such as at study entry. The later course of the disease or
further information emerging might require different treatment
decisions or suggests that a different classiﬁcation may be more
appropriate than the one initially attributed. For example, patients
initially classiﬁed to have permanent AF were at times treated
with a successful cardioversion later during their hospital stay.
Conﬂicts in the assignment to the different clinical entities
appear unavoidable from a retrospective point of view, especially
as current treatment options have the potential to alter the
natural course of the disease. This is highlighted by current cathe-
ter ablation techniques, which may provide ‘cure’ from ‘long-
lasting persistent’ AF, a path not considered in the current
AF classiﬁcation.
Rate vs. rhythm control
Current guidelines recommend the decision to treat with either
rate or rhythm control to be guided by the symptomatic status
of the patient, as no survival beneﬁt of a rhythm control strategy
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Table 4 Drug therapy at discharge/end of visit
First detected
10.8% (n 5 1035)
Paroxysmal
30.2% (n 5 2893)
Persistent
19.5% (n 5 1873)
Permanent
32.8% (n 5 3141)
P-value
Anti-thrombotic
Low-molecular-weight heparin (%) 12.2 10.1 10.7 5.1 *
Heparin (%) 1.1 0.6 1.3 0.6 ,0.05
Oral anticoagulation (%) 47.8 55.6 74.4 70.7 *
Aspirin (%) 30.0 25.8 16.1 20.6 *
Clopidogrel (%) 8.8 6.3 5.9 5.0 *
Combination of the above (%) 17.2 14.2 14.8 9.0 *
None (%) 20.5 17.9 9.0 8.6 *
Anti-arrhythmic/rate control
Class I (%)
Quinidine (%) 0.0 0.1 0.1 0.0
Disopyramide (%) 0.0 0.0 0.1 0.0
Other class IA (%) 0.0 0.0 0.1 0.0
Flecainide (%) 3.5 14.7 7.9 1.1 *
Propafenone (%) 0.9 2.9 1.2 0.5 *
Verapamil and quinidine (%) 0.0 0.1 0.1 0.0
Beta-blocker (class II) (%) 73.7 67.4 70.8 59.2 *
Class III (%)
Sotalol (%) 1.9 5.3 2.0 2.3 *
Amiodarone (%) 7.1 13.8 13.1 4.4 *
Class IV (%)
Diltiazem (%) 0.2 0.6 0.7 1.0
Verapamil (%) 4.8 4.4 5.2 10.2 *
Other class IV (%) 0.0 0.0 0.0 0.0
Digitalis (%) 28.6 21.4 35.2 50.9 *
Other medication
ACE inhibitor (%) 48.8 39.1 51.0 51.5 *
AT II antagonist (%) 13.5 15.3 15.5 17.6 ,0.01
Dihydropyridine (%) 16.2 12.8 12.0 13.8
Diuretics (%) 49.1 41.7 57.8 64.7 *
Nitrate (%) 4.8 4.3 6.1 10.9 *
Statin (%) 8.0 10.5 10.2 9.4
Insulin (%) 2.4 1.7 2.6 3.0
Oral antidiabetic drugs (%) 5.7 4.2 5.7 7.8 *
Thyroid hormone therapy (%) 7.5 10.6 9.7 8.7
*Difference with P , 0.001 among the four AF types.
Classiﬁcation of anti-arrhythmic drug according to Vaughan Williams.
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24–26 In daily clinical practice, other factors
appear to importantly inﬂuence the treatment strategy. Focusing
on the subgroup of patients with persistent AF, the impact of
AF-related symptoms on the treatment given appears limited, as
53.4% of the patients with AF-related symptoms and 47.8% of
the patients without symptoms received a rhythm control strategy.
Nevertheless, increasing symptom burden clearly favoured a
rhythm control strategy. Similar observations were made in the
Euro Heart Survey, in which 44% of the patients in the absence
of symptoms and 67% with symptoms received rhythm control
treatment.
10 Follow-up data from the AFNET registry will allow
assessment of long-term effects of treatment strategies on
outcome including complications.
Interventions
Acute success of cardioversions strongly depends on the type
of AF, which is very high in patients with a ﬁrst episode of AF,
irrespective of whether pharmacological or electrical conversion
was applied. In patients with persistent AF, pharmacological
conversion had a much lower success rate (55.9%) than electrical
cardioversion (86.8%). The success rate of electrical cardioversion
compares well with the success rates in controlled trials,
27,28
suggesting that the results of these trials can be transferred into
routine care.
The frequency of catheter ablation applied to patients in this
registry already reﬂects the recent surge in AF ablation procedures
in daily clinical practice.
29 This relates to procedures performed
before enrolment as well as after inclusion in the registry. In fact,
the rate of AF ablation is more in line with the latest version of
the ACC/AHA/ESC guidelines on AF
6 published after the patient
enrolment ended. This indicates a rapid communication of novel
Figure 3 Anti-thrombotic treatment of patients eligible and
ineligible for oral anticoagulation according to the ACC/AHA/
ESC Guidelines 2001, applicable during recruitment of the
patients. Stroke risk factors are given in Appendix 1. Overall,
71.4% of the eligible patients received anticoagulation (oral antic-
oagulation or low-molecular-weight heparin for anticoagulation
purposes). In patients not eligible, anticoagulation was given in
49.4%. OAC, oral anticoagulation; LMWH, low-molecular-weight
heparin; antiplatelet, aspirin, clopidogrel, or ticlopidine.
...............................................................................................................................................................................
Table 5 Stroke risk factors
First detected
10.8% (n 5 1035)
Paroxysmal
30.2% (n 5 2893)
Persistent
19.5% (n 5 1873)
Permanent
32.8% (n 5 3141)
P-value
Stroke risk factors
Age  75 years (%) 27.7 19.9 26.3 39.0 *
Heart failure or LVEF  35% or severely
impaired systolic LV function on TTE (%)
28.4 18.8 35.7 36.8 *
Hypertension (%) 68.9 65.9 70.6 71.1
Mitral stenosis (%) 0.9 1.2 2.2 3.3 *
Valve replacement (%) 2.4 3.9 4.3 7.6 *
Stroke/TIA (%) 5.4 7.8 9.8 11.6 *
Age 60–74 years and diabetes or CAD (%) 13.6 15.5 18.0 17.1
At least one of the above (%) 82.5 77.4 86.3 90.2 *
Overt hyperthyroidism (%) 3.9 3.3 5.1 4.0
Mean CHADS2 score 1.6 + 1.1 1.4 + 1.1 1.8 + 1.2 2.0 + 1.3 *
CHADS2 score  2 (%) 49.4 38.8 53.4 62.1 *
CHADS2 score  3 (%) 20.0 15.5 26.8 32.7 *
Contraindications
Major bleeding (%) 0.9 1.5 2.2 2.8 *
Prior cerebral haemorrhage (%) 0.1 0.4 0.5 0.6
Malignancy (%) 7.2 7.4 7.3 9.6 *
LVEF, left ventricular ejection fraction; TTE, transthoracic echocardiography; TIA, transient ischaemic attack; CAD, coronary artery disease; CHADS2, stroke-risk index: recent
congestive heart failure, history of hypertension, age  75 years, diabetes mellitus (1 point each), and prior cerebral ischaemia (2 points).
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M. Nabauer et al. 430therapeutic modalities within the AFNET study centres to provide
optimal care to the patients.
Anticoagulation
Prevention of stroke remains a major treatment goal in AF and is
usually achieved by the administration of oral anticoagulants to
patients considered at high risk for stroke.
5,7,30,31 Reports from
the last 15 years, however, indicate that oral anticoagulation
remains signiﬁcantly underused in AF.
32,33 Based on the ACC/
AHA/ESC 2001 guidelines,
5 effective throughout enrolment of
the patients in this registry, 90.8% of the patients included would
be considered at high or very high risk for stroke, mandating antic-
oagulation therapy (Figure 3). Of 7194 patients eligible, 5136
(71.4%) received anticoagulation (oral anticoagulation or LMWH
for anticoagulation purpose), which ranks among the highest
rates reported. It is similar to the anticoagulation rate reported
in the Euro Heart Survey (67%), which was conducted primarily
among specialized centres of cardiology in Europe, most of them
supported by an anticoagulation clinic to monitor the INR.
10 The
similarity in the rate of anticoagulation may relate to the fact
that the majority of the patients in this registry were also recruited
by specialized university hospitals and cardiologists (together
67.0%).
Considering that 28.4% of the patients eligible for oral anticoa-
gulation did not receive such a treatment, it has to be kept in mind
that in clinical practice, anticoagulation treatment is highly depen-
dent on the individual patient and takes into account factors
such as age, feasibility of adequate monitoring of therapy,
co-morbidities, and the patient’s lifestyle and personal preference.
Thus, the decision not to give anticoagulant therapy for a patient
eligible for anticoagulation may still be the most appropriate strat-
egy for that individual.
In contrast, anticoagulation therapy (oral anticoagulation or
LMWH) was also given to 351 of the 710 (49.4%) patients with
a low or very low risk of stroke when anticoagulation is not rec-
ommended by ACC/AHA/ESC 2001 guidelines. Even though half
of the patients at low or very low risk of stroke received oral anti-
coagulation, this is, by absolute numbers, only a small fraction of
the patients. In some of these patients, diseases other than AF
(e.g. prior pulmonary embolism or deep venous thrombosis,
pulmonary hypertension) may have justiﬁed oral anticoagulation.
Still, some of them appear to have been exposed to the inconve-
nience of oral anticoagulation, along with the risk of bleeding,
without any foreseeable beneﬁts.
Limitations
The inclusion of various levels of medical care is a major advantage
of this registry and will help gain a more representative picture of
patients with AF than previous registries focusing on selected
patients from specialized centres of cardiology.
9,10 Although a
balanced recruitment of patients for this registry was intended,
university and academic medical centres contributed slightly
more patients than smaller hospitals and practising cardiologists.
Compared with these three groups, patients cared for by internists
and general practitioners were signiﬁcantly underrepresented. This
has to be taken into account when extrapolating from these data
to the general population.
Conclusions
Most patients included in the registry have AF associated with one
or multiple concomitant conditions, most importantly hyperten-
sion. Although the sudden onset of AF may suggest it to be an
acute disease, it has to be recognized that AF originates from long-
term substrate alterations by cardiac and non-cardiac diseases.
These data support current ‘comprehensive’ treatment strategies
for the prevention of AF in general and for the prevention of
progression to permanent AF. The use of oral anticoagulation in
high-risk patients is among the highest reported, indicating that
the need for anticoagulation in these patients is well established
in daily medical care for patients with AF in Germany. In contrast,
decisions on rate and rhythm control do not appear to be
strictly guided by current guideline recommendations. Long-term
follow-up of the patients in this registry will determine the conse-
quences of guideline adherence on complications and survival.
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Appendix 1: deﬁnitions
First detected episode of atrial ﬁbrillation
Episode of AF diagnosed for the ﬁrst time, recognizing that there may
be uncertainty about the duration of the episode and about previous
undetected episodes.
Paroxysmal atrial ﬁbrillation
Recurrent AF that terminates spontaneously and generally lasts less
than or equal to 7 days (usually ,24 h).
Persistent atrial ﬁbrillation
Recurrent or sustained AF that does not terminate spontaneously and
usually lasts more than 7 days; termination with pharmacological
therapy or electrical cardioversion does not change the designation.
Permanent atrial ﬁbrillation
Long-standing AF in which cardioversion has failed or has not been
attempted.
Idiopathic/lone atrial ﬁbrillation
Applies to young individuals under 60 years without clinical or echo-
cardiographic evidence of cardiac disease.
Characteristics of patients with AF 431Symptomatic atrial ﬁbrillation
The presence of one or more of the following symptoms: palpitations,
chest pain, dyspnoea, dizziness, fatigue.
Rhythm control strategy
A rhythm control strategy was assumed when pharmacological or
electrical cardioversion was performed or planned, or ablation for
AF performed or planned, or class IA, IC, or III anti-arrhythmic
drugs (Vaughan Williams classiﬁcation
34) were prescribed.
Rate control strategy
Patients were considered on rate control if no drugs or interventions
used for rhythm control strategy were applied.
Eligible for anticoagulation
Eligibility for anticoagulation was decided on the basis of the criteria of
the ACC/AHA/ESC Guidelines 2001
5 and included the following risk
factors for stroke: age  60 years and diabetes or coronary artery
disease, age  75 years, heart failure, left ventricular ejection fraction
 0.35, overt hyperthyroidism, hypertension, mitral valve stenosis,
valve replacement, or prior thrombo-embolism. Patients undergoing
pharmacological or electrical cardioversion or catheter ablation were
also considered to be eligible for anticoagulation. Patients with poten-
tial contraindications for oral anticoagulation, deﬁned as prior cerebral
haemorrhage, major bleeding, or malignancy were excluded.
Not eligible for anticoagulation
If not meeting the above criteria for eligibility, patients were con-
sidered ineligible for oral anticoagulation.
Low-molecular-weight heparin for
anticoagulation
When low-molecular-weight heparin was used as bridging therapy
with initiation of oral anticoagulation within 7 days, it was counted
as oral anticoagulation therapy at the time of discharge.
Mean New York Heart Association class
Only patients classiﬁed as NYHA class I–IV were included in the
calculation.
Appendix 2: organization of the
AFNET registry
The German Competence Network on Atrial Fibrillation (AFNET)—
founded in 2003—is an interdisciplinary national research network
sponsored by the Federal Ministry of Education and Research
(BMBF). The network currently consists of clinicians in more than
100 hospitals and more than 200 ofﬁce-based cardiologists, internists,
and general practitioners and university-based researchers coordinat-
ing the activities. AFNET aims at improving care of patients with AF
by promoting research, medical services, and information in emerging
diagnostic and therapeutic ﬁelds in AF.
Board: G.B. (Speaker), Mu ¨nster; Thomas Meinertz, Hamburg; U.R.,
Dresden; G.S., Munich.
Steering Committee: Thomas Fetsch, Mu ¨nchen; Andreas Go ¨tte,
Magdeburg; P.K., Mu ¨nster; T.L., Bonn; M.O., Brandenburg; Karl
Wegscheider, Hamburg; Thomas Weiß, Mu ¨nster.
Advisory Board: Maurits Allessie (Maastricht, The Netherlands); Peter
Bauer (Vienna, Austria); Stefan Gesenhues (Ochtrup, Germany);
Robert Hatala (Bratislava, Slovakia); Lukas Kappenberger (Lausanne,
Switzerland); Ruth Strasser (Dresden, Germany); Hein J.J. Wellens
(Maastricht, The Netherlands); Karl Werdan (Halle, Germany);
Stefan Willich (Berlin, Germany).
Appendix 3: contributing centres
Reginal coordinating centres
Dietrich Andresen, Klinikum am Urban, Berlin; G.B., Universita ¨tsklini-
kum Mu ¨nster, Mu ¨nster; Meinrad Gawaz, Universita ¨tsklinikum
Tu ¨bingen, Tu ¨bingen; Andreas Go ¨tte, Universita ¨tsklinikum Magdeburg,
Magdeburg; Gerd Hindricks, Herzzentrum Leipzig, Leipzig; Karl-Heinz
Kuck, Asklepios Klinik St Georg, Hamburg; T.L., Universita ¨tsklinikum
Bonn, Bonn; Thomas Meinertz, Universita ¨res Herzzentrum Hamburg
gGmbH, Hamburg; M.O., Klinikum Brandenburg, Brandenburg;
Patrick Schauerte, Universita ¨tsklinikum Aachen, Aachen; G.S.,
Universita ¨tsklinikum Großhadern, Mu ¨nchen; Christian Wolpert,
Universita ¨tsklinikum Mannheim, Mannheim; Manfred Zehender,
Universita ¨tsklinikum Freiburg, Freiburg.
Study centres
Ju ¨rgen Atmanspacher, Kreiskrankenhaus Mittleres Erzgebirge,
Zschopau; C. Axthelm, Klinikum Pirna, Pirna; Peter Baumgart, Clemen-
shospital Mu ¨nster, Mu ¨nster; Hubert Birkenheier, St Augustinus Kran-
kenhaus, Du ¨ren; Hermann Bo ¨nisch, St Elisabeth Hospital, Beckum;
Jo ¨rn Budelmann, Krankenhaus Allgemeines Krankenhaus Bergedorf,
Hamburg; Ute Czerwinski, Stadtkrankenhaus Calbe, Calbe/Saale;
Harald Darius,Vivantes Klinikum Neuko ¨lln, Berlin; Heinrich Degen, St
Nikolaus Stiftshospital GmbH, Andernach; Hermann-Josef Dieckmann,
Sta ¨dtisches Hellmig-Krankenhaus, Kamen; Nicolas Doll, Herzzentrum
Leipzig Herzchirurgie, Leipzig; Thomas Dorsel, Josephs-Hospital
Warendorf, Warendorf; Franz Dotzer, Klinikum Garmisch-
Partenkirchen, Garmisch-Partenkirchen; Eckart Frantz, St Josefs-
Krankenhaus, Linnich; J. Frese, Klinikum Pinneberg, Pinneberg; Heribert
Fritz, Medizinisches Zentrum Kreis Aachen Betreuungsteil Marienho ¨he,
Wu ¨rselen; Rainer Hauck, Kreiskrankenhaus Bad Reichenhall, Bad
Reichenhall; Bernd Hayen, Klinikverbund Bassum/Sulingen, Basum;
P. Herold, Klinikum Prenzlauer Berg, Berlin; Manfred Heßler, Krei-
skrankenhaus Belzig, Belzig; Ellen Hoffmann, Sta ¨dtisches Klinikum
Mu ¨nchen GmbH, Mu ¨nchen; Hugo A. Katus, Uniklinik Heidelberg,
Heidelberg; Elisabeth Kauder, Krankenhaus Tuttlingen, Tuttlingen;
Michael Kentsch, Klinium Itzehoe, Itzehoe; Peter Kleine-Kaltho ¨fer, St
Franziskus-Hospital, Mu ¨nster; Tilmann Kolbe, Kreisklinik Fu ¨rstenfeld-
bruck, Fu ¨rstenfeldbruck; Andrea Kopitzko, Vivantes Humboldt Klini-
kum, Berlin; Marie-Louise Leutermann-Oeinck, Euregio Klinik,
Nordhorn; Gu ¨nter Lockert, Elbeklinikum Stade, Stade; Eckard Marg,
Landesklinik Brandenburg, Brandenburg; Matschuck, Klinikum St
Georg gGmbH, Leipzig; Jo ¨rg Maurus, OSK Krankenhaus Wangen,
Wangen; Paul Milz, Malteser Krankenhaus St-Brigida, Simmerath;
Andreas Mu ¨gge, Berufsgenossenschaftliches Klinikum Bergmannsheil,
Bochum; Peter Mu ¨ller, Klinikum Nord, Hamburg; Stefan Mu ¨ller-Lissner,
Parkklinik Weissensee, Berlin; Ute Nauke, Pfeiffersche Stiftungen, Mag-
deburg; Ulrich Nellessen, Johanniter Krankenhaus Stendal, Stendal;
Ngiuyendin, Elisabeth Krankenhaus Essen, Essen; Ochs, Evangelisches
Diakonie Krankenhaus Freiburg, Freiburg; Hermann Rudolf Ochs,
Marienkrankenhaus Soest, Soest; Heyder Omran, St Marien-
Hospital Bonn, Bonn; Pfaffenbach, Bethlehem Krankenhaus Stolberg,
Stolberg; O. Popovic-Panic, Evangelisches und Johanniter-Krankenhaus,
Dierdorf-Selters; Ulrike Reinke, Herz-Jesu-Krankenhaus, Mu ¨nster;
Ekkehard Schnieber, Johanniter Krankenhaus Geesthacht, Geesthacht;
Frank Scho ¨ning, DRK Krankenhaus Teterow, Teterow; Heinz-Peter
Schultheiss, Uniklinikum Benjamin-Franklin, Berlin; Richard Schu ¨rmann,
M. Nabauer et al. 432Kreiskrankenhaus Leer, Leer; Anselm Sellier, Krankenhaus Schwab-
mu ¨nchen, Schwabmu ¨nchen; Claus Spieker, Raphaelsklinik, Mu ¨nster;
Ulrich Tebbe, Klinikum Lippe-Detmold Detmold; Ralph To ¨lg, Segeber-
ger Kliniken GmbH, Bad Segeberg; Harald Trautmann, DRK Kranken-
haus Am Bu ¨rgerpark, Bremerhaven; Peter Trenkwalder, Krankenhaus
des Landkreises Starnberg, Starnberg; R. Uebis, Klinikum Aschaffen-
burg, Aschaffenburg; Tilmann Unger, Kreiskrankenhaus des Bo ¨rdek-
reises, Oschersleben; E. von Hodenburg, Herzzentrum Lahr, Lahr;
Wettengel, Herzzentrum Brandenburg in Bernau, Bernau; Dietmar
Wietholt, Klinikum Uelzen, Uelzen.
Ofﬁce-based physicians
Ayham Al-Zoebi, Wermsdorf; K.-F. Appel, Ambulantes Herzzentrum
Kassel, Kassel; Roland Armbruster, Weingarten; Wolfgang Baar,
Andernach; Rainer Bartsch, Birkenwerder; Thomas Batz-Scharlinger,
Freiburg; Gerhard Bauer, Bad Mergentheim; Jens Beermann, Wedel;
Heinrich Beyer, Lu ¨beck; Heinz Bleschke, Neubrandenburg; Rolf
Busch, Lu ¨dighausen; Bayram Civilibal, Berlin; Wilfried Da ¨nschel,
Ambulantes Herzzentrum Chemnitz, Chemnitz; Christoph Dempe,
Calw; M. Diefenbach, Bru ¨hl; Torsten Donaubauer, Oschatz; Brigitte
Dressel, Zeitz; Hans-Holger Ebert, G. Stenzel, Riesa; Edelmann,
Delitzsch; Marianne Eisenschmidt, Brandenburg; Klaus Eiser, Bad
Neuenahr-Ahrweiler; H. Erlemeier, Norderstedt; Udo-Hans Faber.
Ga ¨rtner, Leisnig; Christian Fechtrup, Mu ¨nster; Alfred Fichtmu ¨ller,
Weißenfels; Frank Fischer, Ludwigshafen; Ralf Frieske, Aachen; Ingrid
Funk, Freiburg; Matthias Gabelmann, Kirchzarten; Jenny Ga ¨rtner,
Leisnig; Manfred Geiger, Praxis Mathey/Schofer, Hamburg; Hans
Geller, Aachen; Norbert Gerich-Du ¨sseldorf, Aachen; Martin Gerke,
Arnsberg; Markus Goertz, Linnich; Werner Go ¨ring, Erkenbrechtswei-
ler; Yvonne Grafen, Geilenkirchen; Kathrin Gross, Mu ¨nchen; Ju ¨rgen
Haase, Brandenburg; Hansjo ¨rg Hahn, Brandenburg; So ¨ren Heik,
Hamburg; Gerhard Held, Hamburg; Ralf Hewing, Mu ¨nster; Peter Hoff-
mann, Rainer Hoffmann, Wertheim; Hartmut Hoppe, Havixbeck;
Andrea Hostert, Bad Neuenahr; Thomas Huber-Abel, Schwab-
mu ¨nchen; Frank-Michael Isbruch, Castrop-Rauxel; Eberhard Johannes,
Hamburg; Bernd Kallenberg, R. Neumann, Stolberg; Werner
Kempen, Aachen; Johannes Kern, Leipzig; Kleinecke-Pohl, Ko ¨ln;
Rainer Kohl, Gemeinschaftspraxis fu ¨r Herz- und Gefa ¨ßkrankheiten,
Mannheim; Ulrich Ko ¨hler, Kardiologische Praxisklinik Ludwigshafen,
Ludwigshafen; M. Kro ¨smann, Mu ¨nster; Ulla Krug, Mu ¨nchen; Bernd
Ku ¨hnert, Freiburg; Hermann Lahmeyer, Sontheim; Bernd-Ulrich
Langer, Axel Langer, Miesbach; Volker Laske, Hannover; Matthias
Lo ¨be, Weißbrodt, Leipzig; Adelheid Lueb, Hamburg; Christian Lu ¨er,
Heide; Bergfried Mertins, Naumburg; Werner Metz, Leonberg; Erik
Meyer, E. Horstkotte, Bremen; Frank Mibach, Itzehoe; Annette
Nagel, Taucha; Walter Nahrendorf, Magdeburg; Mohammed Natour,
Heidelberg; Jost Neubert, Rathenow; Dieter Oster, Boppard; Eva
Pfannmu ¨ller-Schurr, Kornwestheim; Gudrun Pichelbauer, Brandenburg;
Jo ¨rg Piroth, Aachen; Bernhard Plappert, Calw; Fred Pru ¨nte, Bonn;
Waltraud Retter, Berlin; Hans-Joachim Riechardt, Brandenburg;
Werner Rieker, Berlin; Christel Robotham, Neustadt; Franz-Rudolf
Ro ¨hrig, Bonn; Werner Rosenberger, E. Feder, Garmisch-Partenkirchen;
Hans-Eckart Sarnighausen, Lu ¨neburg; Peter Schaefer, Aachen; Thomas
Scheibner, Ebersbach; Achim Schick, Mu ¨nster; Michael Schilp, Man-
nheim; Petra Schirdewahn, Salzmu ¨nde; Veronika Schleicher-Schlosser,
Aachen; Philipp Schley, Viersen; Christmaria Schlu ¨ter, Hamburg;
Reinhard Schmidt, Bad Honnef; Diethold Schneider, Gerd Schneider,
Freiburg; Norbert Scho ¨n, Mu ¨hldorf; Thomas Scho ¨nfelder, Eschweiler;
Wilko Schoormans, Schleswig; M. Schreiner, Leipzig; Thomas
Schro ¨der, Hamburg; Wolfgang Schulz-Weiling, Freiburg; Michael
Schumacher, Wolmirstedt; H. Seemann, Winsen; Henning Seevers,
Hamburg; Claudia Sick, Leipzig; Frank Sonntag, Henstedt-Ulzburg;
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Bernd Wagner, Leipzig; Max Weber, Castrucci, Mu ¨nster; Marcus
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